The explosion in cell therapy development companies has fueled a need to develop well-characterized clinical products which has resulted in the call for robust and validated analytical assays now being louder and more important than ever before.
The inaugural Cell Therapy Analytical Development Summit brings you the leaders in CMC, analytics and process development to create standardized and automated analytical techniques and technologies for improved therapeutic characterization at scale.
Join over 100 of the world's experts as we discuss how to navigate a murky regulatory landscape, robustly validate assays and advance the characterization of CAR-T and TCR cell therapy analytics to ensure safe, consistent and quality cell therapy products.
Get involved this December to:
- Address the need to fully understand the mechanism of action of a cell therapy to develop representative potency assays
- Assess methods to develop functional assays suitable for routine and timely testing to overcome operational constraints
- Explore ways to develop non-destructive and non-invasive in-line analytics
- Discuss current techniques being developed to standardize flow cytometry and explores ways to overcome batch effects
- Highlight sources of variability in cell counting measurement such as environmental, procedural, analytical and instrumental, and techniques to minimize variability
Why do experts attend our cell therapy summits?
"Moments where we can come together with passionate individuals and companies who are focused on advancing cancer care are inspiring, and the Cell Therapy Summit is no different. We are energized by the discussions about cell therapy and its potential applications for bringing new therapies to patients in need."
"This is a best in class and top summit in the cell therapy area which is an invaluable asset to both industries and academia."
- University of Pennsylvania
GOLD: Conference + 2 Workshops: USD 3597.0,
SILVER: Conference + 1 Workshop: USD 3298.0,
BRONZE: Conference Only: USD 2999.0,
Workshop Only: USD 499.0
Speakers: Branly Orban, Senior Manager, CAR-T Quality Control Molecular Bioanalysis, Celgene, Tam Soden, Senior Director and Head of Analytical Development, Kite Pharma, Therese Choquette, Analytical Project Lead, Senior Fellow, Novartis, Eric Alonzo, Senior Scientist, Cell Analytics, Bluebird Bio, Jean-Pierre Cabaniols, Head of the Analytical Department, Cellectis, Jennifer Dashnau, Senior Director, Head of Analytical Development and Quality Control, Century Therapeutics, Lawrence Lamb, CSO, Incysus, Sarah Snykers, Quality Control Manager, Celyad, Steven Feldman, Director, Manufacturing and Process Development, Stanford School of Medicine, Ajit Kamath, Analytical Development Scientist, Mustang Bio, Franco Marincola, CSO, Refuge Biotech, Laura Pierce, Biomedical Engineer, NIST, Stacey Cranert, Senior Scientist, Poseida Therapeutics, Stephanie Mgebroff, Director, Research Quality Control, Seattle Children's Institute, Tamara Laskowski, Senior Research Scientist, Immunotherapy, MD Anderson Center, Alexey Bersenev, Director, Advanced Cell Therapy Lab, Yale University, Amber Giles, Associate Director, Process Development, Neo-Antigen, Kite Pharma, Barrett Nehilla, Analytical Development, Torque Therapeutics, Mahwish Natalia, Senior Scientist, Takeda, Michael Leek, CEO, TCBiopharm, Rozanna Yaing, SVP, Quality and Regulatory Affairs, Incysus